Avantor, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AVTR in the last 30 days.
See all $AVTR insider activity →Avantor (NYSE: AVTR) reported Q3 2026 net sales of $1.7B, up 4.6% YoY, with organic growth of 5.2%. GAAP EPS was $0.30, and adjusted EPS was $0.22. The company raised FY 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow. VWR Distribution & Services saw 5.8% organic growth, while Bioscience & Medtech Products returned to organic growth at 3.6%.
Longleaf Partners Fund's Q3 2026 letter notes Avantor (AVTR) stock rose over 50% due to market confidence in its growth and turnaround plan. AVTR's VWR business returned to organic growth, while Bioprocessing showed order improvements. The firm trimmed its position as the stock neared its value target. AVTR closed at $16.62 with a $11.24B market cap, posting a 45.03% YTD pullback.
Avantor, Inc.'s average stock price target increased from $14.85 to $15.04, with estimates ranging from $12 to $19. This implies a 2% downside from the Oct. 8 closing price. The consensus rating remains 'Hold' among 19 analysts, with 2 Buys, 15 Holds, and 2 Sells.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning AVTR (Avantor, Inc.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 1 bearish.
Recent AVTR coverage spans earnings, financial news and corporate actions.
Positive earnings surprise and upgraded guidance likely support the stock.
Fund commentary notes strong price rally and organic growth outlook.
The modest target increase suggests limited upside and slight pressure as the new target still indicates a downside.
The announcement sets the date for the upcoming earnings release; no new financial data is provided.
New CFO appointment may signal strategic shift and affect investor perception of financial leadership.
AlphAI scores every news story that mentions AVTR with an AI model for sentiment and relevance, and aggregates insider trades from Avantor, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Avantor (NYSE: AVTR) reported Q3 2026 net sales of $1.7B, up 4.6% YoY, with organic growth of 5.2%. GAAP EPS was $0.30, and adjusted EPS was $0.22. The company raised FY 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow. VWR Distribution & Services saw 5.8% organic growth, while Bioscience & Medtech Products returned to organic growth at 3.6%.
2 min readLongleaf Partners Fund's Q3 2026 letter notes Avantor (AVTR) stock rose over 50% due to market confidence in its growth and turnaround plan. AVTR's VWR business returned to organic growth, while Bioprocessing showed order improvements. The firm trimmed its position as the stock neared its value target. AVTR closed at $16.62 with a $11.24B market cap, posting a 45.03% YTD pullback.
1 min readAvantor, Inc.'s average stock price target increased from $14.85 to $15.04, with estimates ranging from $12 to $19. This implies a 2% downside from the Oct. 8 closing price. The consensus rating remains 'Hold' among 19 analysts, with 2 Buys, 15 Holds, and 2 Sells.
1 min readAvantor, Inc. (NYSE: AVTR) will release its Q3 2026 earnings on October 28, 2026, before market open, followed by a conference call at 8:00 a.m. ET. The webcast will be available live and as a replay for 30 days on the company's investor relations website.
1 min readAvantor, Inc. (AVTR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Avantor appoints new Chief Financial Officer RADNOR, Pa. – September 21, 2026 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technolog
2 min readAvantor, Inc. (AVTR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 21, 2026, Avantor, Inc. (the “Company”), announced the appointment of Todd Garner as Executive Vice President
1 min readAvantor (AVTR) raised its full-year revenue and earnings guidance after Q2 2026 results, despite noting softness in Bioscience & Medtech Products. The stock has seen a 15.6% 30-day gain and 62.9% 90-day gain, but long-term returns remain negative. Analysts' consensus price target is $14.56, suggesting a 7% overvaluation, with targets ranging from $12.0 to $19.0. The P/S ratio is 1.6x, lower than industry and peer averages.
2 min readBruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.
3 min readBio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.
3 min readAvantor (AVTR) received a Buy rating from Zacks, with upward revisions to its full-year earnings estimates. Analysts are optimistic about its earnings outlook, despite flat sales and declining net income in Q2 2026. The company projects $7.1 billion revenue and $651.0 million earnings by 2029, requiring 2.8% yearly revenue growth and a $1,229.0 million earnings increase from -$578.0 million today.
2 min read
